智冉医疗完成超3亿元A轮融资，专注于研发新一代侵入式柔性脑机接口平台

Core Viewpoint - Beijing Zhirun Medical Technology Co., Ltd. has completed over 300 million RMB in Series A financing, indicating strong market recognition of its technology and commercialization prospects [3] Group 1: Company Overview - Zhirun Medical focuses on developing a next-generation invasive flexible brain-computer interface (BCI) platform, aiming to revolutionize human-machine interaction [4][5] - Since its establishment in 2022, Zhirun Medical has raised nearly 500 million RMB in total funding, reflecting significant investor confidence in its technological direction [3] Group 2: Technology and Innovation - The invasive BCI technology is gaining attention due to its high bandwidth capabilities, which surpass non-invasive and semi-invasive methods in signal acquisition and neural control [5] - Zhirun Medical has chosen the challenging invasive technology route, similar to Elon Musk's Neuralink, based on a deep understanding of BCI technology's essence [5][6] Group 3: Key Technical Developments - The core of invasive BCI development lies in electrode technology, with Zhirun Medical pioneering high-throughput flexible electrodes that have received patent authorization in both China and the U.S. [7] - The company's innovative design addresses electrode displacement issues, significantly reducing inflammation and ensuring long-term signal stability [7][10] Group 4: Strategic Positioning and Future Plans - Zhirun Medical has established a complete closed-loop system from R&D to large-scale production, ensuring full control over clinical-grade products [10] - The company is well-positioned to leverage recent government policies aimed at promoting BCI industry innovation, aligning its strategy with national objectives [10][11] Group 5: Market Potential and Investor Sentiment - Investors express strong confidence in the commercial potential of invasive BCI technology, highlighting Zhirun Medical's unique position in the market and its comprehensive approach to technology development [11][12] - The company is seen as a leading contender in the BCI field, with expectations for its technology to address unmet medical needs and expand into various applications [11][12][12]